Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE)
NCT ID: NCT05457491
Last Updated: 2024-10-04
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
56 participants
INTERVENTIONAL
2021-10-01
2022-07-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hypertrophic Scar Prevention by Novel Topical Gel Application
NCT03403621
Tranexamic Acid in Treatment of Facial Erythema
NCT05897918
Efficacy of Methyl Aminolevulinate + Daylight in Patients With Facial Photodamage
NCT02139618
Tripeptide/Hexapeptide Topical and Hybrid Laser Treatment for Acne Scarring
NCT04606134
A Trial of Pulse Dyed Laser (Chromogenex Regenlite Transform) in the Treatment of Inflammatory Acne Vulgaris
NCT02647528
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Human platelet extract (HPE)
Subjects will follow a standardized twice daily skin care regimen of applying morning and night. Morning skin care routine includes Vanicream Gentle Facial Cleanser, human platelet extract, and EltaMD UV Daily Broad-Spectrum SPF 40, or Vanicream Lite Lotion. Evening skin care routine includes Vanicream Gentle Facial cleanser, human platelet extract, and EltaMD PM Therapy Facial Moisturizer or Vanicream Lite Lotion
Human platelet extract (cosmetic product)
A leukocyte depleted allogeneic product derived from human U.S. sourced pooled apheresed platelets (derived from screened healthy donors). Applied to face twice daily for 12 weeks.
Vanicream Gentle Facial Cleanser
A mild cleanser specifically formulated for daily facial use. Applied to face twice daily for 12 weeks
EltaMD UV Daily Broad-Spectrum SPF 40
A daily moisturizer with a lightweight formula that provides broad-spectrum sunscreen protection. EltaMD UV Daily Broad-Spectrum SPF 40 provides powerful protection against the sun's harmful UV rays, as it hydrates and is gentle enough for post-procedure skin. Powered by hyaluronic acid, this face sunscreen plumps the skin with lightweight moisture, while micronized zinc and octinoxate shield skin from UVA/UVB rays to prevent the visible signs of environmentally caused aging. Applied to face once daily for 12 weeks.
EltaMD PM Therapy Facial Moisturizer
A fortifying face moisturizer to repair elasticity and vitality. EltaMD PM Therapy Facial Moisturizer restores youthfulness while strengthening the skin's natural moisture barrier. Niacinamide blends with antioxidants to boost the skin color and tone, as it speeds up the skin's repair processes. Rice protein peptides aid in encouraging cell growth, promoting collagen formation and improving elasticity. Applied to face once daily for 12 weeks.
Vanicream Lite Lotion
Lotion to restore and maintain a normal moisture level. Applied to face twice daily for 12 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Human platelet extract (cosmetic product)
A leukocyte depleted allogeneic product derived from human U.S. sourced pooled apheresed platelets (derived from screened healthy donors). Applied to face twice daily for 12 weeks.
Vanicream Gentle Facial Cleanser
A mild cleanser specifically formulated for daily facial use. Applied to face twice daily for 12 weeks
EltaMD UV Daily Broad-Spectrum SPF 40
A daily moisturizer with a lightweight formula that provides broad-spectrum sunscreen protection. EltaMD UV Daily Broad-Spectrum SPF 40 provides powerful protection against the sun's harmful UV rays, as it hydrates and is gentle enough for post-procedure skin. Powered by hyaluronic acid, this face sunscreen plumps the skin with lightweight moisture, while micronized zinc and octinoxate shield skin from UVA/UVB rays to prevent the visible signs of environmentally caused aging. Applied to face once daily for 12 weeks.
EltaMD PM Therapy Facial Moisturizer
A fortifying face moisturizer to repair elasticity and vitality. EltaMD PM Therapy Facial Moisturizer restores youthfulness while strengthening the skin's natural moisture barrier. Niacinamide blends with antioxidants to boost the skin color and tone, as it speeds up the skin's repair processes. Rice protein peptides aid in encouraging cell growth, promoting collagen formation and improving elasticity. Applied to face once daily for 12 weeks.
Vanicream Lite Lotion
Lotion to restore and maintain a normal moisture level. Applied to face twice daily for 12 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All skin phototypes ≥ grade I of Fitzpatrick's classification.
* Mild-to-moderate global face wrinkles and mild-to-moderate global fine lines based on a modified Griffiths' 10-point scale \[3\].
* Fully understanding of the requirements of the study and willingness to comply with the treatment plan, including laboratory tests, diagnostic imaging, and follow-up visits and assessments.
* Volunteer willingness to discontinue any other anti-aging topical or parenteral treatments for the duration of the study.
* Can provide written informed consent and complete HIPAA documentation after the nature of the study is fully explained and prior to any study-related treatment.
* Can provide written informed consent to being photographed for purposes of treatment for medical, scientific purposes.
Exclusion Criteria
* Subjects who have had an antiaging or aesthetic treatment prior to the study: Botox or Botox-like products, peelings, plastic surgery, resurfacing with Laser, Intense pulsed light (IPL) therapy, threats, radiofrequency treatments, hyaluronic acid treatment, Plasma-Rich Platelets treatment, or any other specific treatments prone to change the skin aspect during the last 6 months
* Individuals with a history of any dermatological disease or condition, including but not limited to active atopic dermatitis, psoriasis, eczema, active seasonal allergies, collagen diseases, or skin cancer involving the treated sites within the past 6 months
* Cutaneous marks on the experimental area which could interfere with the assessment of skin reactions (pigmentation problems, scar elements, over-developed pilosity, ephelides, and nevi in too great quantity, sunburn, beauty spots, freckles, etc.)
* Participants with asymmetric photodamage on dorsal hands due to environmental exposures (i.e., golfing) and/or other skin lesions including burns or scars resulting in significant skin surface variability between dorsal hands
* Eczematous reaction still visible, scar, or pigmentary sequelae of previous tests on the experimental area
* Allergy to colophony or nickel.
* Allergy or reactivity to drugs, food or cosmetic products previously observed, including perfumes or cologne products.
* Skin hyper-reactivity.
* Forecast of intensive sun, tanning bed use or UV phototherapy during the test period.
* Treatment with prescription-strength Vitamin A acid or its derivatives within 3 months before the beginning of the study.
* Treatment with topical steroids on the experimental area within 16 days before the study.
Study constraints:
* No application of products on the experimental area (except the suggested ones), particularly any anti-aging cosmetic products except for sunscreen.
* No change in hygiene habits
* No application of any cosmetic moisturizing products on the face or any makeup on face and lips, on the day of study evaluations
* No change in the way of life or in the physical activity
* No change in dietary activities, or any treatment that significantly impacts body weight
* No exfoliating treatment on the experimental areas
* Description of any treatment undertaken during the study and all eventual deviations
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Saranya P. Wyles
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Saranya P Wyles, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21-008529
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.